Tag: AptaTargets
Merck assumes clinical development and commercialisation of stroke drug ApTOLL
AptaTargets has announced an agreement with German pharmaceutical giant Merck—signed in October 2024—for the clinical development and commercialisation of ApTOLL, a Toll-like receptor 4...
AptaTargets announces publication of APRIL trial data in JAMA Neurology
As per a press release from AptaTargets, JAMA Neurology has published positive results from APRIL—a Phase 1b/2a clinical trial evaluating the safety and efficacy...
Neuroprotective agent linked to reduced death and disability in ischaemic stroke...
ApTOLL, a neuroprotectant medication intended to shield the brain from tissue damage, has been linked to reduced death and disability when used alongside standard...
